I couldn't find a reference to the 200k units by 2014, was that...

I couldn't find a reference to the 200k units by 2014, was that mentioned at the AGM? if this is right (and just throwing some numbers out there for potential)...

200,000 units @ $750 per unit revenue then $150m p.a

At 70% gross margin on each unit then $105m p.a

Cost of admin, marketing and distribution?? say $40m p.a

Then EBIT perhaps $65m p.a?

Then A PE of 15, you get a market cap of $1b!!

and a share price of... $3.00 (just saying!)

and they are talking a potential of 10-14 million procedures annually that recell "could" be used for - thats mind boggling in regard to value

First mover advantage - tick
Disruptive - tick
Huge Potential - tick
Good management - tick
On track -tick
Exciting ride to come - tick, tick, tick

Downside... failure of first management a few years ago (they seem to be well over this and have learnt), potential competitor? (nothing on immediate horizon), slow uptake (yes, but these things seem to go exponential), FDA reject trial (well, with the DoD involved I doubt it as you couldn't ask for a better partner).

So on balance massive upside potential and some downside risk, now its just time...

GLA

Maddoc